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Two common variants in transforming growth factor-b receptor 1 (TGFBR1), TGFBR1*6A and Int7G24A, A allele, have been shown
to act as low-penetrance tumour susceptibility alleles in several common cancers, including breast cancer. We evaluated the TGFBR1
9A/6A and Int7G24A variant frequencies in two breast cancer cohorts; a population-based cohort of breast cancer with defined
family history (n¼459) and in breast cancer patients from a familial cancer clinic (n¼340) and in 856 controls from the Stockholm
region. The familial patients from both cohorts were further divided into high- and low-risk familial breast cancer based on pedigree
analysis. There was no overall association with either variant and breast cancer risk. The TGFBR1*6A allelic frequency was, however,
higher in low-risk familial breast cancer (0.138), compared to controls (0.106; P¼0.04). No significant difference was found in the
high-risk familial (0.102) or sporadic cases (0.109; P¼0.83 and 0.83, respectively). TGFBR1*6A carrier status was further associated
with a high-grade sporadic breast cancer (odds ratio: 2.27; 95% confidence interval: 1.01–5.11; P¼0.049). These results indicate that
the TGFBR1*6A variant may be associated with an increased risk of low-risk familial breast cancer and might be a marker for poorly
differentiated breast cancer. The Int7G24A variant was not associated with breast cancer risk or clinical presentation of the disease
including prognosis in our material.
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Breast cancer is the most common female malignancy in the
Western countries (Parkin et al, 1999), and in Sweden about 6600
new cases are diagnosed annually (The National Board of Health
and Welfare, 2007). Although the majority of breast cancer cases
are sporadic, approximately 25–30% exhibit a familial clustering
and 5–10% do have a hereditary component (Newman et al, 1988;
Margolin et al, 2006). Mutations in the known high-risk genes,
BRCA1, BRCA2, p53, ATM and PTEN, account for less than 25% of
the familial risk for breast cancer, and in the Stockholm region the
frequency of mutations in BRCA1 and BRCA2 is less than 10% in
families with three or more cases with breast cancer (Arver et al,
2001; Thompson and Easton, 2004). It is reasonable that the
remaining breast cancer families carry mutations in as yet
unidentified high-penetrance genes, or are due to the combined
effects of a large number of low-penetrance genes acting in a
multiplicative manner (Pharoah et al, 2002). The latter hypothesis
may also partly explain the development of sporadic breast cancer.
Disrupted transforming growth factor-b (TGF-b) signalling is
involved in the development of various types of cancer. As one of
the key effectors of TGF-b signalling, TGF-b receptor 1 (TGFBR1)
mediates the growth-inhibitory signals from TGF-b through a
complex with TGFBR2. Growing epidemiological evidence indi-
cates that common variants of the TGF-b pathway receptors that
alter TGF-b signalling can modify cancer risk (Kaklamani and
Pasche, 2004). Two common alleles in the TGFBR1 gene,
TGFBR1*6A and Int7G24A, A allele, which reside in exon 1 and
intron 7, respectively, have been reported to act as low-penetrance
tumour susceptibility alleles (Chen et al, 1999, 2004, 2006; Pasche
et al, 1999, 2004; Baxter et al, 2002; Kaklamani et al, 2003; Zhang
et al, 2003; Bian et al, 2005; Kaklamani and Pasche, 2005).
TGFBR1*6A has a deletion of three alanines within a stretch of
nine alanines. Functional investigations have shown that
TGFBR1*6A is an impaired mediator of TGF-b antiproliferative
signals compared with intact TGFBR1 (Chen et al, 1999; Pasche
et al, 1999). Several studies including a meta-analysis of 12 studies
have demonstrated that TGFBR1*6A acts as a low-penetrance
tumour susceptibility allele in the development of colon, cervix,
breast, and ovarian cancer as well as haematological malignancies
(Chen et al, 1999; Pasche et al, 1999, 2004; Baxter et al,
2002; Kaklamani et al, 2003; Bian et al, 2005; Kaklamani and
Pasche, 2005).
The Int7G24A variant causes a G-A transversion in the þ24
position of the donor splice site in intron 7 of TGFBR1. Although
the functional role of this variant is still to be elucidated, Int7G24A
has been found to increase the risk of kidney and bladder cancer
and homozygous carriers have more than 3-fold increased risk of
developing non-small-cell lung cancer (NSCLC) (Zhang et al, 2003;
Chen et al, 2004). A case–control study indicated that this intronic
variant allele was significantly more prevalent in invasive and
metastatic breast cancer cases and may represent a marker for
breast cancer progression (Chen et al, 2006).
In the present study, we evaluated the frequencies of TGFBR1
9A/6A and Int7G24A variants in two breast cancer cohorts with a
defined family history and controls from Stockholm, Sweden and
also examined whether these variants were associated with tumour
presentation and prognosis.
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Material
Familial risk cohort Three hundred and forty familial cases
collected at the Department of Clinical Genetics at Karolinska
University Hospital, Stockholm were used for the study. These
patients had either been referred due to a breast cancer diagnosis
and a family history of breast cancer or had been included as part
of a previous research project on familial breast cancer (Lindblom,
1993). All cases had proceeded through genetic counselling and
those who met the current criteria for BRCA1/2 screening had been
screened negative (Arver et al, 2001). For these cases, there was no
information on tumour characteristics or prognosis.
Population-based cohort Patients with a surgically treated
primary invasive breast cancer admitted to the Department of
Oncology at Huddinge Hospital and So ¨der Hospital (covering the
population of southern Stockholm of 850000 people) from October
1998 to May 2000 were asked participate in a study on genetic risk
factors from breast cancer (Margolin et al, 2004). Family history,
age at diagnosis, hormone receptor status and histology of the
tumour were obtained from all cases, and the median follow-up
was 5 years. This cohort consists of 489 patients in total and 459
patients were used in this study due to logistic reasons. The
samples had previously been screened for mutations in exon 11 of
BRCA1 (11). Four cases with known BRCA1 or BRCA2 mutations
were excluded from the study.
The familial cases were divided into two groups based on
pedigree analysis. Families with at least two first- or second-degree
relatives with breast cancer in addition to the proband, regardless
of age, were classified as high-risk breast cancer families. In this
group, a dominant mode of inheritance is suggested. Cases with
one first- or second-degree relative with breast cancer were
classified as low-risk familial breast cancer, and in this group the
mode of inheritance is unclear. This classification is not ideal from
a risk-estimation point of view since the age factor is omitted but
may reflect monogenic vs polygenic susceptibility better than a
more strict estimation of breast cancer risk.
The mean age in the cases from the Department of Clinical
Genetics was 54 years (24–92 years). In the cases from the
Department of Oncology, the mean age was 60 years (27–88 years),
and there was no statistically significant difference between familial
and sporadic cases (mean age 59 and 61 years, respectively).
As controls, we used DNA from 856 blood donors of mixed
gender collected at Karolinska University Hospital, Stockholm,
Sweden.
The ethical committee at the Karolinska Institute approved of
the study.
Methods
TGFBR1*6A genotyping PCR amplification of exon 1 was
performed with the following primers: Fwd-50-FamGAGGCGAGG
TTTGCTGGGGTGAGG-30 and Rev-50-CATGTTTGAGAAAGAGCA
GGAGCG-30. The reactions were performed using supplied
protocol for GC-rich fragments (Invitrogen, Paisley, UK) in a total
volume of 25ml containing 50ng DNA and 1.25U Platinum
s Taq
DNA polymerase (Invitrogen). The fluorescently labelled PCR
products were then separated on an ABI 377 DNA Sequencer
(Applied Biosystems, Foster City, CA, USA). The genotypes were
analysed using the GENESCANt and GENOTYPERt software
(Applied Biosystems). A product size of 247bp represented the
wild-type TGFBR1 (9A) allele, whereas a product size of 255bp
represented the TGFBR1*6A allele.
Int7G24A genotyping Genotyping primers for the Int7G24A
variant were Fwd-50TGTCTGAAAGGAGGTTCATCC-30 and Rev-
50-GAACAACTTCTGCTCATGACG-30. The PCR was carried out in
a total volume of 25ml containing 50ng DNA and 0.625U
AmpliTaq Gold
s DNA polymerase (Applied Biosystems). A total
volume of 10ml PCR product was digested using 3U of Bsr1
restriction enzyme in 1  NEBuffer3 at 651C for 8h. The digested
DNA products were then separated in a 2.5% agarose gel and
visualised by ethidium bromide staining. Bsr1 cuts the wild-type
Int7G24A sequence while the Bsr1 restriction site is eliminated by
the variant allele. For all identified variant carriers and for
approximately 25% of the wild-type samples, restriction enzyme
digestion was replicated after a second independent PCR
amplification to confirm the allele calling. The concordance rate
was 100%.
Statistical analysis
The allelic frequency was analysed by the w
2-test. Genotype
distribution in breast cancer cases and controls was tested for the
Hardy–Weinberg equilibrium, and the two variants were shown to
be in the Hardy–Weinberg equilibrium in both cases and controls.
Genotype data were compared between the groups using
univariate logistic regression analysis for binomial and ordinal
responses. For the ordinal response variable grade, we used a
model where each non-reference category was contrasted with the
reference category (grade 1). Results are presented as odds ratios
(ORs) with 95% test-based confidence intervals (CIs). No
correction for multiple statistical testing was performed.
RESULTS
TGFBR1*6A genotypes were scored for 95.6% (764 out of 799) and
100% (856 out of 856) of the cases and controls, respectively,
corresponding to genotype results for 309 sporadic, 254 low-risk
and 201 high-risk familial cases and 856 controls. The Int7G24A
variant was successfully genotyped in 96.0% (767 out of 799) of the
cases and 99.6% (853 out of 856) of the controls, with genotype
results for 311 sporadic, 250 low-risk and 206 high-risk cases and
853 controls.
There was no overall association with TGFBR1 6A allele and
breast cancer, neither in the familial risk cohort (P¼0.17) nor in
the population-based cohort (P¼0.25) compared to controls
(Table 1a).
The TGFBR1*6A variant was found to be associated with an
increased risk for breast cancer in the low-risk familial breast
cancer group (Table 1b). The TGFBR1*6A allelic frequency was
0.138 in the low-risk familial cases compared to 0.106 in the
controls (P¼0.04) corresponding to an OR for *6A carriers of 1.3
(95% CI: 1.0–1.9). The OR for *6A/*9A and *6A/*6A genotypes
was 1.3 (95% CI: 0.9–1.8) and 2.1 (95% CI: 0.8–6.0), respectively,
in this group. There was no difference in the TGFBR1*6A
frequency in sporadic or high-risk familial breast cancer compared
to controls (Table 1b). In addition to the *9A and *6A alleles, the
*11A allele was detected in one sporadic breast cancer case, and
*5A, *7A and *10A were detected in the controls.
The genotype distribution and allelic frequency of Int7G24A in
the breast cancer cases and controls are provided in Table 2a
and 2b. There was no overall association with this variant and
breast cancer in either cohort (P¼0.25 and 0.20, respectively,
Table 2a). The A-allele frequency was slightly more common
among low-risk familial (0.208) or sporadic breast cancer group
(0.203) than among controls (0.183); however, this difference was
not statistically significant. The ORs for Int7G24A carriers, GA
heterozygotes and AA homozygotes, in these two groups all
exceeded 1. The A-allele frequency was lower in the high-risk
familial breast cancer group (0.158) compared to the controls,
corresponding to ORs of A-allele carriers, including both
heterozygotes and homozygotes, lower than 1 (Table 2b).
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Department of Oncology at Huddinge and So ¨dersjukhuset
Hospital, information on tumour grade, stage, ER and PR
status and recurrence was available. The frequency of TGFBR1*6A
carriers among patients diagnosed with grade 3 tumours
was higher than among patients diagnosed with grade 1 tumours
(OR: 2.27; 95% CI: 1.01–5.11; P¼0.049, Table 3). There was
no association of TGFBR1*6A with other clinical parameters,
including tumour stage, ER and PR status at diagnosis and
recurrence. In addition, no association was found between
Table 1a TGFBR1*6A genotypes in controls and in two Stockholm breast cancer cohorts
Controls (n¼856)
a
Familial risk cohort (n¼327) Population-based cohort (n¼437)
TGFBR1*6A genotypes No. of cases (%) No. of cases (%) OR (95% CI) No. of cases (%) OR (95% CI)
9A/9A 682 (79.7) 250 (76.4) 1.0 348 (79.6) 1.0
6A/9A 160 (18.7) 72 (22.0) 1.2 (0.9–1.7) 80 (18.3) 1.0 (0.7–1.3)
6A/6A 10 (1.2) 5 (1.5) 1.4 (0.5–4.0) 8 (1.8) 1.6 (0.6–4.0)
6A/9A+6A/6A 170 (19.9) 77 (23.5) 1.2 (0.9–1.7) 88 (20.1) 1.0 (0.8–1.3)
6A-allele freq. 0.11 0.12 0.11
P-value
z 0.17 0.25
CI¼confidence interval; OR¼odds ratio.
aIncluding the rare allele genotypes such as 5A, 7A, 10A and 11A.
zP-value for 6A-allele frequency comparison using w
2-test.
Table 1b TGFBR1*6A genotypes in controls, high-risk and low-risk familial and sporadic breast cancer cases
Controls
(n¼856)
a
High-risk familial breast
cancer (n¼201)
Low-risk familial breast
cancer (n¼254)
Sporadic breast cancer
(n¼309)
a
TGFBR1*6A
genotypes
No. of cases
(%)
No. of cases
(%)
OR (95%
CI)
No. of cases
(%)
OR (95%
CI)
No. of cases
(%)
OR (95%
CI)
9A/9A 682 (79.7) 162 (80.6) 1.0 190 (74.8) 1.0 246 (79.6) 1.0
6A/9A 160 (18.7) 37 (18.4) 1.0 (0.7–1.4) 58 (22.8) 1.3 (0.9–1.8) 57 (18.4) 1.0 (0.7–1.4)
6A/6A 10 (1.2) 2 (1.0) 0.8 (0.2–3.9) 6 (2.4) 2.1 (0.8–6.0) 5 (1.6) 1.4 (0.5–4.1)
6A/9A+6A/6A 170 (19.9) 39 (19.4) 1.0 (0.7–1.4) 64 (25.2) 1.3 (1.0–1.9) 62 (20.1) 1.0 (0.7–1.4)
6A-allele freq. 0.106 0.102 0.138 0.109
P-value
z 0.83 0.04 0.83
CI¼confidence interval; OR¼odds ratio.
aIncluding the rare allele genotypes such as 5A, 7A, 10A and 11A.
zP-value for 6A-allele frequency comparison using w
2-test.
Table 2a Int7G24A genotypes in controls and in two Stockholm breast cancer cohorts
Controls (n¼853)
Familial risk cohort (n¼323) Population-based cohort (n¼444)
Int7G24A genotypes No. of cases (%) No. of cases (%) OR (95% CI) No. of cases (%) OR (95% CI)
GG 559 (65.5) 222 (68.7) 1.0 278 (62.6) 1.0
GA 265 (31.1) 93 (28.8) 0.9 (0.7–1.2) 145 (32.7) 1.1 (0.9–1.4)
AA 29 (3.4) 8 (2.5) 0.7 (0.3–1.5) 21 (4.7) 1.5 (0.8–2.6)
GA+AA 294 (34.5) 101 (31.3) 0.9 (0.7–1.1) 166 (37.4) 1.1 (0.9–1.4)
A-allele freq. 0.183 0.169 0.211
P-value
z 0.25 0.20
CI¼confidence interval; OR¼odds ratio.
zP-value for A-allele frequency comparison using w
2-test.
Table 2b Int7G24A genotypes in controls, high-risk and low-risk familial and sporadic breast cancer cases
Controls
(n¼853)
High-risk familial breast
cancer (n¼206)
Low-risk familial breast
caner (n¼250) Sporadic breast cancer (n¼311)
Int7G24A
genotypes
No. of cases
(%)
No. of cases
(%)
OR
(95% CI)
No. of cases
(%)
OR (95%
CI)
No. of cases
(%)
OR
(95% CI)
GG 559 (65.5) 147 (71.4) 1.0 157 (62.8) 1.0 197 (63.3) 1.0
GA 265 (31.1) 53 (25.7) 0.8 (0.5–1.1) 82 (32.8) 1.1 (0.8–1.5) 102 (32.8) 1.1 (0.8–1.4)
AA 29 (3.4) 6 (2.9) 0.8 (0.3–1.9) 11 (4.4) 1.3 (0.7–2.8) 12 (3.9) 1.17 (0.6–2.3)
GA+AA 294 (34.5) 59 (28.6) 0.8 (0.5–1.1) 93 (37.2) 1.1 (0.8–1.5) 114 (36.7) 1.10 (0.8–1.4)
A-allele freq. 0.183 0.158 0.208 0.203
P-value
z 0.14 0.35 0.47
CI¼confidence interval; OR¼odds ratio.
zP-value for A-allele frequency comparison using w
2-test.
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above (Table 3).
DISCUSSION
The role of TGFBR1*6A variant in breast cancer is controversial
(Baxter et al, 2002; Jin et al, 2004; Kaklamani and Pasche, 2005).
Baxter et al (2002) investigated the TGFBR1*6A variant in 355
breast cancer cases and 248 controls. Their results indicated that
the *6A allelic frequency was significantly higher in breast cancer
patients compared to the controls. This result was further
supported by a meta-analysis from 2004 on TGFRB1*6A and
cancer susceptibility where there was a significant association of
the variant with breast cancer. The OR for breast cancer was 1.38
(95% CI: 1.14–1.67) for carriers of the 6A allele, this figure based
on 1400 breast cancer cases from seven different studies, including
the Baxter study (Pasche et al, 2004). However, in a study of eight
variants including the *6A variant in Finnish unselected and Polish
familial breast cancer cases, there was no association neither of any
of the variants nor of haplotypes (Jin et al, 2004).
There are several explanations for difficulties reaching con-
clusive results on variants in candidate low-penetrance genes such
as TGFRB1*6A. Association studies on variants conferring modest
risks require large sample sizes; the study size is, however, also
depending on variant frequency. The study size can be reduced by
selecting cases enriched for genetic susceptibly such as patients
with family history or bilateral cases (Houlston and Peto, 2004).
We therefore chose to analyse the genotype distribution and allelic
frequency of TGFBR1*6A in two cohorts of patients with a well-
defined family history and classified the patients in high- and
low-risk family history and sporadic breast cancer. There was no
overall association with the TGFRB1*6A variant and breast cancer
in either of our breast cancer cohorts. Our results indicate that the
TGFBR1*6A variant might confer an increased risk of breast
cancer in families classified as having a low-risk familial history,
even though there was only statistical significance on the allelic
level, and not in the genotype distribution. This therefore needs to
be confirmed. Breast cancer tumours in TGFBR1*6A carriers were
also slightly more poorly differentiated, indicating that the
TGFBR1*6A variant might be associated with tumour grade even
though our material of grade III tumours (n¼75), from the
population-based cohort, is small and the association of borderline
significance only. Moreover, this result needs to be confirmed in a
larger material.
Studies on Int7G24A are rare. This variant has been reported to
be associated with NSCLC, kidney and bladder cancer suscep-
tibility (Zhang et al, 2003; Chen et al, 2004). Patients with
invasive and metastatic breast cancer have been reported to
have a higher frequency of Int7G24A, and this variant may
represent a marker for breast cancer progression (Chen et al,
2006). No studies have to date been published on this variant in
familial breast cancer. In the present study, we compared the
genotype distribution and allelic frequency of Int7G24A in 206
high-risk and 250 low-risk familial breast cancer cases, 311
sporadic breast cancer cases and 853 controls. The frequency of
the Int7G24A variant in low-risk familial and sporadic breast
cancer cases was higher compared to the controls, the OR for
Int7G24A carriers and GA homozygotes and AA homozygotes as
well, but the difference did not reach statistical significance. The
Int7G24A variant may have an increased risk for low-risk familial
and sporadic breast cancer, and this needs to be confirmed by a
larger sample size.
In the high-risk familial breast cancer group, we found the
frequency of both TGFBR1 variants to be lower than among the
controls. The different results obtained from subgrouping the
families into high and low risk support the hypothesis that
different genetic models might operate in these two groups of
patients.
The controls in this study were blood donors of mixed gender
from the same region. It has been suggested that matching for
gender may not be relevant unless the variant causes early gender-
specific mortality (which would result in a deviation from the
Hardy–Weinberg equilibrium) (Hemminki and Forsti, 2002).
The two variants of the TGFBR1 gene in our controls were shown
to be in the Hardy–Weinberg equilibrium. Chen et al (2004) found
the A-allele frequency in male and female controls to be similar
(0.137 and 0.145, respectively). A possible age difference between
Table 3 Association of TGFBR1*6A genotypes with clinical parameters
TGFBR1*6A genotypes Int7G24A genotypes
Total
cases
a
Available
cases 9A/9A
6A/
9A+6A/
6A
OR
(95% CI) P-values
Total
cases
Available
cases GG GA+AA
OR
(95% CI) P-values
Grade 309 274
a 311 275
1
b 71 60 11 1.0 71 45 26 1.0
2 127 103 24 1.3 (0.6–2.8) 0.55 129 77 52 1.2 (0.6–2.1) 0.61
3 75 53 22 2.3 (1.0–5.1) 0.05 75 49 26 0.9 (0.5–1.8) 0.81
Stage 309 309
a 311 311
Stage I/II
b 273 218 55 1.0 277 176 101 1.0
Stage III/IV 35 28 7 1.0 (0.4–2.4) 0.98 34 22 12 0.9 (0.4–2.0) 0.89
ER status 309 293
a 311 294
Positive
b 245 196 49 1.0 247 154 93 1.0
Negative 47 37 10 1.1 (0.5–2.3) 0.84 47 31 16 0.9 (0.4–1.6) 0.64
PR status 309 261
a 311 261
Positive
b 199 162 37 1.0 200 123 77 1.0
Negative 61 44 17 1.7 (0.9–3.3) 0.12 61 40 21 0.8 (0.5–1.5) 0.57
Recurrence 309 298
a 311 297
No
b 245 197 48 1.0 245 153 92 1.0
Yes 52 43 9 0.9 (0.4–1.9) 0.70 52 35 17 0.8 (0.4–1.5) 0.51
CI¼confidence interval; OR¼odds ratio.
aIncluding the rare genotype 11A.
bWere used as the reference.
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mean age and thus not had time to develop a breast tumour, could
cause a false-negative result (Pasche et al, 1999; Kaklamani and
Pasche, 2005).
In conclusion, there was no overall association of the TGFBR1
variants *6A and Int7G24A and breast cancer in two breast
cancer cohorts from the Stockholm region. The *6A variant
seems to confer an increased risk of low-risk familial breast
cancer. The Int7G24A variant may be associated with the
development of low-risk familial and sporadic breast cancer;
however, this needs to be confirmed in a larger material.
Furthermore, the *6A variant might be linked to poorly
differentiated breast cancer.
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